Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.

Adv Ther · 2021 · PMC8107068 · PMID 33730350

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A comparative real-world analysis of 88 Taiwanese patients with brain metastases at baseline showed a trend towards a reduction in risk among patients treated with afatinib compared with gefitinib [ 31 ] (Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.